Johnson & Johnson
JNJHealthcare Drug Manufacturers General
Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −95.8%
- Free cash flow
- −21.4%
- Total debt
- −9.16%
Quarter to September 2026, against a year earlier
Follow JNJ
Alert me
Johnson & Johnson (JNJ) EV/FCF
As of Nov 19, 2026, Johnson & Johnson (JNJ) trades at a EV/FCF of 31.5×. Over the past ten years it has ranged from 12.0× (August 2015) to 35.0× (June 2026); the current reading is higher than 99% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 25.3× | 46.80% |
| FY2024 | 17.3× | (21.30%) |
| FY2023 | 21.9× | (17.66%) |
| FY2022 | 26.6× | 21.57% |
| FY2021 | 21.9× | 6.50% |
| FY2020 | 20.6× | 21.40% |
| FY2019 | 17.0× | 4.08% |
| FY2018 | 16.3× | (17.50%) |
| FY2017 | 19.7× | 11.51% |
| FY2016 | 17.7× | 33.69% |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 31.3× | 13.17% |
| Jun 2026 | 27.6× | (16.52%) |
| Mar 2026 | 33.1× | 30.60% |
| Dec 2025 | 25.3× | 8.77% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| GILD Gilead Sciences, Inc. compare | 16.4× |
| PFE Pfizer Inc. compare | 18.7× |
| NVS Novartis AG compare | 22.9× |
| MRK Merck & Co., Inc. compare | 24.9× |
| ABBV AbbVie Inc. compare | 30.3× |
| AMGN Amgen Inc. compare | 30.4× |
| JNJ Johnson & Johnson | 31.5× |
| AZN AstraZeneca PLC compare | 46.6× |
| LLY Eli Lilly and Company compare | 57.4× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on JNJ
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement